Alexei is a surgeon and serial entrepreneur with two successful exits thus far. In his most notable role as founding CEO of SIA, he led the company through FDA-clearance, commercialization, NIH grant funding for a “first-and-only” indication in a new market, and pivotal trial initiation to achieve that indication. SIA achieved all this in less than four years and with only $6.3M in equity capital, while maintaining a developmental pipeline. After kicking off a $15M Series B fundraise that would later be oversubscribed and expanded, Alexei began his training in plastic surgery at Northwestern McGaw Medical Center. He remained active as an executive board member during his first 18 months of surgical residency, leading the process that culminated in SIA being acquired by Integra LifeSciences (Nasdaq: IART) in December of 2022. Following the completion of three years of surgical residency, he is now taking a sabbatical as he considers his next step.

In addition to his work at SIA, in 2020, Alexei simultaneously co-founded RapidRona, a shared-economy platform that connects clinical laboratories directly to consumers, and one of the first companies to bring a home PCR test to market. They were acquired by DMH in 2021. He has authored over 20 peer-reviewed publications and book chapters, and lectures on science and entrepreneurship at national and international meetings. He is listed as inventor on multiple patents and serves as an investor and board advisor to early-stage companies focused on nanotechnology, tissue engineering, radiofrequency ablation, and transseptal puncture. Alexei was also named one of Forbes’ “30 under 30” in 2018 and Crain’s “20 in their 20s” in 2019.